Pharmafile Logo

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Corporate Equity Survey

Our client’s senior management wanted to assess its company’s image amongst their key HCP stakeholders. The client wanted to measure familiarity and perceptions of the company versus its competitors, particularly...

Webcast: Capturing the “moments-of-truth” using online communities and bulletin boards

MROCs and bulletin boards are growing in popularity because they offer specific benefits over or alongside more traditional methodologies – providing the opportunity to create a panel of geographically disperse...

Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017

Living with Ulcerative Colitis (UC) is a study conducted amongst 110 adult UC patients in the US. The study employs a mixed quantitative/qualitative methodology and is available to purchase alongside...

20 questions: Round 5

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month we asked our US employees about office life in Philadelphia.Watch the video: https://www.researchpartnership.com/news/2017/08/20-questions-round-5/

Research Partnership publishes 2017 Living with NASH report

Healthcare market research and consultancy specialist Research Partnership has published a new Living with Non-alcoholic Steatohepatitis (NASH) report for 2017.Living with Non-alcoholic Steatohepatitis (NASH) is a quantitative US study conducted online amongst patients....

Blending qual and quant – the benefits of a hybrid approach

My colleague Chris Gaj and I recently conducted a video dialogue on the topic of hybrid qual/quant methods in which we discussed why clients often want to blend the two, and the...

Multi-level Segmentation Solution

Our client has an established product for multiple indications. They wanted to create a HCP segmentation typing tool which could be implemented in-field to help classify physicians across two different...

Global health care specialists from coast to coast

Published in Quirk's Faces of Marketing Research August 2017

Demand assessment research video

Head of Business Analytics Tom Nolte and Associate Director Will Tolley discuss demand assessment research – the various techniques and when in a product's stage of development a demand assessment...

Men vs Women in emerging markets

Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging marketS